BRIEF-Ab Science Says IDMC Recommends Continuation Of masitinib Phase 3 Study With No Requirement To Increase Sample Size
Jan 4 (Reuters) – AB SCIENCE SA: * REG-AB SCIENCE ANNOUNCES THAT BASED ON INTERIM ANALYSIS, IDMC RECOMMENDED THE CONTINUATION OF THE MASITINIB PHASE 3 STUDY IN PROGRESSIVE MULTIPLE SCLEROSIS WITH NO REQUIREMENT TO INCREASE THE SAMPLE SIZE * FINAL RESULTS OF STUDY ARE EXPECTED IN Q2 2019 * IDMC DID NOT REPORT ANY SAFETY CONCERN WITH MASITINIB IN STUDY POPULATION Source text for Eikon: Further…
View On WordPress













